The statement comes from the CEO of one of the plants that had encountered production problems, the one in Baltimore managed by Emergent BioSolutions, and which is currently still according to what has been revealed.
Words referable mainly to the further ones 24 million doses destined for the US territory, but which inevitably bodes well on the European front as well.
In fact, it should be remembered that last month the company informed the EU that there could be problems in respecting the delivery of 55 million doses agreed by June, of which 7.3 million destined for Italy.
Johnson & Johnson reassures: “We will respect deliveries”
In the United States, the facility that had the greatest problem is based in Baltimore, but has not yet been authorized by the Food and Drug Administration US to produce the vaccine.
Precisely for this reason, the CEO of Emergent, the company that manages the plant,
he talked about problems found on a single lot and that anyway they did not affect on the quality of any of the vaccine doses produced so far.
He then explained that the elimination of a batch turns out to be a usual circumstance, and this should not weigh on production times and therefore on subsequent agreed deliveries.
Even without the Emergent-owned facility, Johnson & Johnson was able to deliver on its commitment to supply 20 million doses to the USA in March, and the company said it was ready to deliver another 24 million in April.
A Biden administration official confirmed that most of the vaccines will continue to arrive since «J&J vaccine arm» of the Netherlands.
Get the latest news delivered to your inbox
Follow us on social media networks